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Available online 19 October 2016Psoriasis is histologically characterized by keratinocytes (KC) hyperproliferation, inﬂammation, and increased
angiogenesis, but the pathological factor responsible for these symptoms is unknown. Here, a neuroendocrine
peptide (prokineticin 2, PK2), is highly expressed in human and mouse psoriatic skins but no signiﬁcant change
in other autoimmune diseases, suggesting that PK2 is a psoriasis-speciﬁc factor. Bacterial products signiﬁcantly
up-regulated PK2, implying that infection induces PK2 over-expression. PK2 promoted KC and macrophage to
produce interleukin-1 (IL-1), the central player of inﬂammation and psoriasis, which acts on adjacent ﬁbroblast
to induce inﬂammatory cascades and KC hyperproliferation. IL-1 feeds back on macrophages to induce PK2 pro-
duction to perpetuate PK2-IL-1 positive feedback loop. PK2 also promoted angiogenesis, another psoriatic symp-
tom. In mouse models, PK2 over-expression aggravated psoriasis while its knock-down inhibited pathological
development. The results indicate that PK2 over-production perpetuates psoriatic symptoms by creating PK-2-
IL-1 vicious loop. PK2 is a central player in psoriasis and a promising psoriasis-speciﬁc target.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Prokineticin2 (PK2), also named Bv8, is a small 8 kDa protein ﬁrst
found in skin secretions of the frog Bombina variegate (Mollay et al.,
1999). It belongs to the PK protein family, which has a conserved N-
terminal sequence of AVITGAand 10 cysteines. Inmammals, the PK pro-
tein family is involved in a number of biological activities such as inges-
tive behaviours, circadian rhythms, angiogenesis, inﬂammation and
inﬂammatory pain. Two closely related G protein-coupled receptors
(PKR1 and PKR2)mediate signal transduction of PKs (Negri et al.,
2004; Shojaei et al., 2008). Psoriasis, a chronic cutaneous disorder
with a spectrum of clinical phenotypes including red, scaly and well-
demarcated skin lesions formed by hyperproliferation of epidermal
keratinocytes (KC), affects approximately 1–3% of theworldwide popu-
lation (Baliwag et al., 2015; Di Meglio et al., 2014; Gottlieb, 2005; Nestle
et al., 2009). Besides causing ecological burdens, psoriasis produces aZoology, Chinese Academy of
ong), rlai@mail.kiz.ac.cn
pen access article under the CC BY-Nsevere psychosocial burden such as anxiety, depression, and perceived
stress, therefore signiﬁcantly impairs the quality of patients' life
(Gupta et al., 2015; Tohid et al., 2016; Villasenor-Park et al., 2012). A
new emerging concept of psoriasis is that psoriasis is a chronic and dis-
abling disease characterized by an immune-mediated inﬂammatory
background involving skin, joints or both, often associated with several
metabolic and non-metabolic comorbid diseases (Coates et al., 2016;
Gupta et al., 2015; Menter, 2016). Given that psoriasis is a chronic dis-
abling disease, the long-term safety is the major critical determinant
driving the choice of treatment (Campanati et al., 2016). However, un-
derstanding of psoriasis has evolved over the years from an epidermal
KC disease to an autoimmune disease to a systemic inﬂammatory dis-
ease (Bachelez, 2005; Nestle et al., 2009); its pathogenesis is still poorly
understood. The mainstay of treatment is topical therapy, but systemic
therapy is considered for the patients with moderate-to-severe disease
who do not respond to topical treatments. The current available con-
ventional systemic treatments are associated with several side effects
over a long time (Asahina et al., 2016; Guerra et al., 2016). Numerous in-
ﬂammatory cytokines, such as IL-17, TNF-а and IL-23, are over-
produced in psoriatic skin, with their levels correlated with the severity
of psoriasis disease (Baliwag et al., 2015; Kofoed et al., 2015). To target
these cytokines in psoriatic disease, some anti-cytokine biologic drugsC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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disease biomarkers, none of these cytokines has so far met the sensitiv-
ity, speciﬁcity, and accuracy criteria that would allow their translation
into clinical use (Villanova et al., 2013). Psoriasis-speciﬁc pathogenesis
has not been identiﬁed although inﬂammatory disorders play important
roles in this disease as in other autoimmune diseases (Ryan et al., 2014).
The cause and mechanism underlying histological symptoms in psoria-
sis skin remain unknown. Especially, several crucial questions for psori-
asis pathogenesis remain to be elucidated including: 1) What is the
initiator of psoriasis and how to initiate it? 2) Why and how do KCs ab-
normally proliferate and differentiate? 3) What is the mechanism trig-
gering processing of IL-1 identiﬁed as a key player in psoriasis
pathogenesis? 4) What is and how to be responsible for abnormal an-
giogenesis, such as dilated and contorted blood vessels in psoriatic le-
sions? 5) How to perpetuate inﬂammatory and angiogenesis disorder?
Here we show that PK2, a multifunctional peptide known to promote
inﬂammation and angiogenesis, plays a key role in psoriatic cell
signaling.
2. Materials and Methods
2.1. Collection of Human Samples and Study Approval
Biopsies of psoriasis skin were obtained from the limbs of 3 different
patients with moderate to severe plaque psoriasis, in which 2 were fe-
males with psoriatic plaque on arms and legs, 1 was a male with psori-
atic plaque on limbs and torso. The Psoriasis Area and Severity Index
(PASI) scores were 19.2, 21.6 and 27.6 respectively. Normal samples
were obtained from limbs of human with no characteristic of any skin
diseases. The 10 samples for IHCwere skin tissues embedded in parafﬁn
blocks and stored for b2 years. All the samples were obtained from the
patients with PASI N 12. The blood samples of healthy controls were ob-
tained from 60 volunteers. Psoriatic blood samples were obtained from
52 psoriatic patients aged 24–62 years with PASI N 12, of which 24were
females and 28 were males. For each disease, 50 blood samples were
taken from patients diagnosed with Crohn's disease, ulcerative colitis,
atherosclerosis and type 1 diabetes mellitus. Human samples were
from the ﬁrst afﬁliated hospital of Kunming Medical University and
the afﬁliated hospital of Jiangnan UniversityWuxi 4th People's Hospital.
The use of human samples for research was approved by the ethical
committees of the local hospitals. In all cases, informed patients consent
was obtained. All the experiments were reviewed and approved by the
internal review board of Kunming Institute of Zoology, Chinese Acade-
my of Sciences (SMKX2016017).
2.2. Animals
K14-VEGF transgenic mice were from State Key Laboratory of
Biotherapy, Cancer Center, Western China Hospital, Sichuan University.
Kunming mice and C57BL/6 mice were purchased from Kunming Med-
ical University. All the experiments complied with national legislation
and were approved by the Committee on the Ethics of Animal Experi-
ments of Kunming Institute of Zoology, Chinese Academy of Sciences
(SYDW2013019).
2.3. Peptide and Antibodies
PK2 was purchased from PeproTech, Inc. (USA). Antibodies of PK2,
CD3, CD31, CD4, CD8, E-selectin and PPARβ were purchased from
Santa Cruz Biotechnology, Inc. (USA); Antibodies of extracellular regu-
lated kinase (ERK), phosphorylated ERK (P-ERK), p38 mitogen-
activated protein kinase (p38 MAPK), P-p38, Jun. N-terminal kinase
(JNK), P-JNK, and β-actinwere purchased from Cell Signaling Technolo-
gy, Inc. (USA); Antibodies of caspase-1 was purchased from Merck
Millipore (USA); Antibodies ofα-smoothmuscle actin (α-SMA), absent
in melanoma 2 (AIM2) were purchased from Abcam (Cambridge, MA,USA). Other chemicals or antibodies without special illustration were
purchased from Sigma-Aldrich (USA).
2.4. Analysis of Skin Extracts by RP-HPLC
Human skin of normal and psoriasis were homogenized by continu-
ously grinding in a cold (4 °C) 1:1 distilledwater/ethanol 96% (v/v)mix-
ture acidiﬁed to pH 3 by the addition of citric acid. Then the suspensions
were centrifuged for 30 min at 4 °C with 6000g and the supernatants
were ﬁltered using an Amicon Ultracel-30 membrane to cut-off size
over 30 kDa (Lande et al., 2007). The ﬁltrate was applied onto a C8
reversed-phase high-performance liquid chromatography column
(RP-HPLC, Hypersil 5 μm C8, 4.6 × 300 mm) and eluted by acetonitrile
gradient. Compared to normal skin, some additional eluted peaks
were observed in the extracts of psoriatic skins and analyzed by quadru-
pole time-of-ﬂight mass spectrometer (Q-TOF2 mass spectrometer;
Waters Micromass) to identify peptides according to the mass. Se-
quences of peptideswere conﬁrmed byMS/MS analyses of Lys-C digests
with nano-electrospray ionization.
2.5. Histological Analysis
After ﬁxation by 4% formalin, tissueswere dehydrated by an increas-
ing concentration of alcohol, embedded in parafﬁn and then sectioned
into 5 μm slices using a histocut (Leica, RM2235, Germany). All sections
were deparafﬁnized and rehydrated for Hematoxylin and Eeosin (H&E)
staining and immunohistochemistry (IHC) analysis. For IHC analysis,
sections were incubated with antibodies against PK2, CD3, CD31, CD4,
CD8,α-SMAand E-selectin, respectively. Immunoreactivitieswere visu-
alized with a horseradish peroxidase-conjugated secondary antibody.
2.6. PK2 Quantitation
IHC was used to investigate the differential expression of PK2 in
skins of psoriasis patients and healthy human, as well as in mouse
skin. PK2 expression in skin of imiquimod–induced psoriasis mouse
model was analyzed by western blot. PK2 concentration in skin and
blood was determined by ELISA (CUSABIO, China), and the procedure
was performed according to the manufacturer's instructions.
2.7. Effects of Bacterial Products and IL-1 on PK2 Production
Raw 264.7 murine macrophage cells were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM, GIBCO, USA) supplemented with
10% fetal bovine serum, 100 units/ml of penicillin, and 100 μg/ml of
streptomycin in a humidiﬁed 5% CO2 atmosphere at 37 °C. 2 × 104
Raw 264.7 murine macrophage cells/well were plated into a 96-well
plate. After overnight incubation, the cells were adhered to the plate.
Then the medium was changed into DMEM supplemented with 1%
fetal bovine serum to starve the cells for 16 h. Bacterial products includ-
ing DNA and lipopolysaccharide (LPS) or IL-1βwere added to the wells
for 24 h of incubation, using the same volume of PBS as blank control. At
the end of incubation, the supernatantswere collected for PK2detection
by ELISA (CUSABIO, China), and the procedure was performed accord-
ing to the manufacturer's instructions.
2.8. Isolation of Fibroblasts (FB) and Keratinocytes (KC) From Newborn
Mice
FB and KCwere isolated from newborn mice skins according to pre-
vious method (Lichti et al., 2008). Kunming newborn mice (1–2-day-
old) were sacriﬁced by deep CO2 narcosis and sterilized. The skins
were removed immediately, and spread out completely and ﬂoated on
cold trypsin (0.25%, w/v, Sigma-Aldrich, without EDTA) with dermis
side down at 4 °C overnight. After trypsin treatment, the skins were
transferred to dry culture dishes with the epidermis side down and
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various points around the edges. The dermis was lifted up straight
above the epidermis. Dermis was transferred into culture dishes con-
taining DMEM (GIBCO, USA) supplemented with 10% FBS, 200 units/
ml of penicillin and 200 μg/ml of streptomycin (GIBCO, USA) for the
preparation of FB. Epidermis was transferred into culture dishes con-
tainingMinimumEssentialMedium (S-MEM, GIBCO, USA) supplement-
edwith 0.2mMCa2+, 8% FBS (v/v) chelatedwith chelex-100 resin (Bio-
Rad, USA), 200 units/ml of penicillin and 200 μg/ml of streptomycin for
the preparation of KC. The suspension of dermis and epidermis were ﬁl-
tered through a 100-μm cell strainer (BD, USA) at 1000 g for 5 min after
they were minced and triturated sufﬁciently. FB and KC were resus-
pended in DMEMand S-MEM (0.2mMCa2+), then transferred into cul-
ture bottles, respectively. After incubation for 24 h, the culture medium
was aspirated and the cellswerewashedwith PBS to discard unattachedFig. 1. Elevated PK2 expression in human psoriasis skin and blood. a, b. PK2 expression analyze
and psoriatic skins. d. ELISA analysis of PK2 in normal, psoriasis, atherosclerosis, Crohn's disease
bacterial DNA, and IL-1β. All the bars represent the average of three independent experimentscells and debris. Enoughmediumwas added to the cells before cultured
in a humidiﬁed 5% CO2 atmosphere at 37 °C (Lichti et al., 2008).
2.9. Cell Proliferation Assay
Cells were seeded in 96-well plates at a density of 1 × 104 cells/well.
For KC and FB co-culture, an in vitro co-culture system of millicell cul-
ture inserts (0.4 μm pore Millipore, USA) was used, with FB in the bot-
tom of the 24-well plates and KC within the inserts. Cell viability was
studied using 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl tetrazolium
bromide (MTT) assay. At the end of the incubation, 10% volume of
5 mg/ml MTT was added to each well for additional 4 h incubation.
Then the millicells were transferred to new 24-well plates, and cells
were dissolved in dimethyl sulfoxide (DMSO). The absorbance at
570 nm was measured on a microplate reader (Epoch Etock, BioTek,d by IHC, PK2-positive staining is marked by red arrows. c. ELISA analysis of PK2 in normal
, ulcerative colitis, and diabetes blood. e. ELISA analysis of PK2 in Raw264.7 induced by LPS,
± SD. Signiﬁcant statistics difference indicated by asterisks (*, P b 0.05; **, P b 0.01).
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termined using the following formula:
%Cell Viability ¼ A570 of treated cells½ 
 100%= A570 of control cells½ 
Cell viability produced by concentrations of PK2 which greater than
control was used for the cell proliferation assay.Fig. 2. Effects of PK2 on FB and KCproliferation and cytokines secretion. a. Effects of PK2 on FB an
c, d. Effects of PK2 on IL-1α and IL-1βproduction inRaw264.7 alone or co-culturedwith FBorKC
FB by ELISA. h–l. Effects of PK2 on mRNA expression of GM-CSF, IL-8, IL-6, IL-10, and KGF in
independent experiments ± SD. Signiﬁcant statistics difference indicated by asterisks (*, P b 0.2.10. Effects of PK2 on Production of Cytokines
Raw264.7murinemacrophage, KC and FB cells (2 × 105)were seed-
ed in 96-well plates and treatedwith PK2 for 48 h. In the systemof KC or
FB co-cultured with Raw 264.7 murine macrophage cells, Raw 264.7
murine macrophage cells were seeded in 24-well plates while KC or
FB was seeded in inserts. In the system of KC co-cultured with FB, FB
was seeded in 24-well plates and KC was seeded in inserts. Cytokines'
expression was measured by ELISA and/or quantitative real-time PCR.
To investigate the function of MAPK signal pathway to IL-1 secretion,dKC proliferationwhen theywere co-cultured. b. Effects of PK2 on IL-1α production inKC.
. e–g. Effects of PK2onGM-CSF, IL-8, and IL-6production inKC, FB, and KCco-culturedwith
FB alone or FB co-cultured with KC by qPCR. All the bars represent the average of three
05; **, P b 0.01).
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(SB203580), JNK(SP600125) (Sigma-Aldrich, USA) for 30 min before
treated with PK2 or LPS, then the release of IL-1β was measured by
ELISA kit (Dakewei, China).
2.11. Quantitative Real-time PCR (qPCR)
RNAwas extracted using RNAprep pure cell kit (Tiangen, China) and
the ﬁrst strand cDNAwas synthesized using ﬁrst strand cDNA synthesis
kit (TaKaRa, China). qPCRwas carried out on the platform of the iQ2 sys-
tem (BioRad Laboratories, Hercules, CA, USA) with SYBR Premix Ex Taq
II kit (TaKaRa, DRR081A) using primers listed in Table S1.
2.12. Western Blot Analysis
Cells were washed twice with ice-cold phosphate-buffered saline
(PBS, 8 g/l NaCl, 0.2 g/l KCl, 0.2 g/l KH2PO4, 3.47 g/l Na2HPO4, pH 7.4)Fig. 3. Effects of PK2 on MAPK signaling pathway in KC (a) and Raw 264.7 (b) and on AIM2 in
independent experiments ± SD. Signiﬁcant statistics difference indicated by asterisks (*, P b 0and collected by centrifugation at 1000 g for 5min. Thewashed cell pel-
lets were resuspended in 100 μl of extraction lysis buffer (50 mM Tris-
HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM EDTA, 1 mM Phenylmethanesulfonyl ﬂuoride (PMSF),
1 μg/ml each of aprotinin, leupeptin, and pepstatin, 1 mM sodium
orthovanadate, and 1 mM NaF) and incubated for 30 min at 4 °C. The
cell lysate was centrifuged at 12,000 g for 10 min to remove cell debris,
followed by quick storage at−70 °C for western blot analysis. Protein
concentration was determined by BCA protein assay kit (Thermo,
USA). A total of 40 μg of protein was subjected to SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) on a gel concentration of 12% and
electro-transferred onto a polyvinylidenediﬂuoride (PVDF) membrane
(Roche Diagnostics GmbH, Germany). The immunoblot PVDF mem-
brane was blocked with 5% non-fat dried milk (BD, USA) dissolved in
Tris-buffered saline tween-20 (TBST, 2.42 g/l Tris base, 8 g/l NaCl, 0.1%
Tween 20, pH 7.6) at room temperature for 2 h. The PVDF membrane
was washed three times with TBST and was incubated overnight withﬂammasome signaling pathway in THP-1 (c). All the bars represent the average of three
.05; **, P b 0.01).
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ary antibody for 1 h at room temperature. After washing with TBST,
membranes were developed with enhanced chemiluminescence kit
(TIANGEN, China) in a dark room.
For KC and Raw264.7 cells, the cells were treatedwith different con-
centrations of PK2 for 15min after treatedwith orwithout LPS for 2 h in
serum – free medium. Then EKR, JNK, P38 and their phosphorylated
proteins were analyzed by western blot as described above. For THP-1
cells, cells were treated with different concentrations of PK2 for
30 min after starved by 2% medium for 16 h. Then AIM2 and caspase-
1 activation were analyzed by western blot.
2.13. Effect of PK2 on Angiogenesis
In vitro angiogenesis formation was evaluated in human umbilical
vein endothelial cells (HUVECs). The cells were cultured in M200medi-
um (GIBCO, USA) supplemented 1 × low serum growth supplement
(LSGS; GIBCO, USA) and 10% fetal bovine serum (FBS) at 37 °C in a hu-
midiﬁed 5% CO2 atmosphere. After detaching by trypsinization, HUVECs
werewashed and resuspended in serum-freeM200medium containing
1× LSGS, and then the cells (1× 105)were seeded into the 96-well plate
pretreated with Matrigel matrix. Cells were incubated with vehicle
(PBS), PK2, or basic ﬁbroblast growth factor (b-FGF) for 6 h. Tubes
were photographed using a microscope (Olympus, Tokyo, Japan).
In vivo angiogenesis formation in the chicken chorioallantoic mem-
brane (CAM) was performed as described (Mousa et al., 2006). Fertil-
ized eggs were incubated at 37 °C and 60% relative humidity in a
forced draught incubator. At day 6, a window opening was punctured
in the shell at the air sac of each egg, and then the sterile ﬁlter disks pre-
incubated with test samples were placed on the CAM. The control eggs
received PBS only. Thewindowopening of eggswas closedwith paraﬁlm,
and the eggs were maintained in the incubator for another 72 h. After
that, the eggs were opened and CAM vasculatures were photographed
using a digital camera (Canon, EOS 60D). The angiogenic response was
evaluated by counting the vessel density using Photoshop CS6.
2.14. Differentiation Assay of HaCaT KC
HaCaT (human keratinocyte cell line) cells were from Kunming Cell
Bank, Kunming Institute of Zoology, Chinese Academy of Science. TheFig. 4. (a & b) PK2 accelerated inﬂammatory phase during wound healing. a. Histopathological
100×: visual ﬁeld of magniﬁed 100 times). b. The statistic of inﬂammatory cells in wound.cells were cultured in DMEM supplemented with 10% FBS. To differen-
tiate to the basal phenotype, HaCaTs were cultured in M154CF medium
(GIBCO, USA) containing 8% fetal bovine serum (chelated with chelex-
100 resin), 100 units/ml penicillin, 100 μg/ml streptomycin, and
0.04 mM Ca2+ for 5 days and kept the conﬂuency of cultures below
75–80%. After that, cells were treated with or without 0.2 nM PK2 for
72 h, keratin 1 (K1), keratin 5 (K5), and involucrin were detected by
qPCR.2.15. Full-thickness Wound Mouse Model
According to our previous method (Mu et al., 2014), after anes-
thetizing with 1% pentobarbital sodium (0.1 ml/20 g body weight),
dorsal hairs were removed and dorsal skin was cleansed with
betadine in male Kunming mice (age 6–8 week). Two full-thickness
skin wounds were created on the back of each mouse using an 8-
mm-diameter biopsy punch and each mouse was caged individually.
Ten micro liters of vehicle (0.9% NaCl solution), PK2 (100 μg/ml) or
recombinant murine EGF (100 μg/ml, PeproTech Inc., USA, positive
control) was applied directly to the wound site twice daily for
seven days (day 1–day 7). Wound healing was monitored by using
IPLab imaging software (BD Biosciences, Bedford, MA, USA). Mice
were sacriﬁced on day 3, 5 and 7 post-wounded and biopsy speci-
mens involving the central part of the wounds were obtained for
light microscopy. Skin sections were prepared for histological and
IHC analysis as mentioned above.2.16. Imiquimod-induced Psoriasis-like Dermatitis in Mice
Twenty C57BL/6 micewere randomly divided into two groups. Con-
trol mice in group 1 were left untreated. Backs of mice in group 2 were
shaved and given a daily topically treatment of imiquimod cream (5%)
(iNova Pharmaceuticals Australia Pty Limited) for 7 days. A blinded pro-
cedure was used to monitor psoriasis-like skin inﬂammation. Clinical
scoring of psoriasis based on the human clinical Psoriasis Area and Se-
verity Index (PASI)was performed. Three variables were evaluated - er-
ythema, scaling, and thickening. Each of them scored independently on
a scale ranging from 0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; 4,
very marked. The cumulative score was a total of the three parameterexamination of mice wound treated by PK2/EGF. (25×: visual ﬁeld of magniﬁed 25 times ;
254 X. He et al. / EBioMedicine 13 (2016) 248–261scores ranging from 0 to 12 and the cumulative score of the mouse be-
tween 8 and 12 was used.
2.17. Plasmids Vector Construction
The coding region of mouse PK2 was ampliﬁed from mouse testis
cDNA by standard PCR and cloned into the EcoRI and BamHI site of
PLVX-puro vector (Clontech Laboratories, Inc., USA). The empty PLVX-
puro vector was used as blank control. The oligonucleotides of shRNA
sequence targeting PK2 (sh-PK2) and its negative control scrambled
shRNA (sh-Scr) sequence were synthesized by Sangon Biotech Ltd.
(Shanghai, China). The sequence of sh-PK2 is: CAUAAGGAUCUGCACA
CCUAUCUCGAGAUAGGUGUGCAGAUCCUUAUGUUUU (Cheng et al.,
2012) while that of sh-Scr is: AGUACUGCUUACGAUACGGUUCAAGC
GACCGUAUCGUAUUAGCAGUACUUUU. The oligonucleotides of sh-PK2
and sh-Scr including the digested site of BamHI and EcoRI were
annealed with their complementary sequences and inserted into the
BamHI and EcoRI site of the RNAi-Ready pSIREN-RetroQ Vector
(Clontech Laboratories, Inc., USA) to form retroviral vectors of psh-PK2
and psh-Scr, respectively. The transfection procedure was performed
according to the manufacturer's instructions.Fig. 5. PK2 promotes differentiation of FB and KC. a, b. PK2 promoted FB differentiation indicate
down-regulation of K1 and K5 expression andup-regulation of involucrin expression. d, e. PK2 u
of three independent experiments ± SD. Signiﬁcant statistics difference indicated by asterisks2.18. Virus Production
The lentiviral vector of PLVX-puro vector and retroviral vector RNAi-
Ready pSIREN-RetroQ vector were used as PK2 over-expression and
knockdown system in this study, respectively. The two vectors were re-
spectively packed with HEK 293T cells and EcoPack™ 2–293 cells. For
each virus preparation, 1.5 × 107 HEK 293T cells or EcoPack™ 2–293
cells were plated in T175 ﬂask for 24 h before transfection. PLVX-puro
empty vector (7 μg) or with PK2 gene and the packaging plasmids in-
cluding pMDlg/PRRE (5.4 μg), Prsv-REV (2.8 μg), and pMD2.G (3.5 μg)
were co-transfected into HEK 293T cells by Fugene 6 (Promega, USA).
Each ﬂask of EcoPack™2–293 cells were transfected with 5 μg psh-
PK2or psh-Scr in 1.5 μl xfect polymer (Clontech, USA) as transfection re-
agent. The transfection procedure was according to manufacturer's
manual. Eight hours later, the medium containing transfection reagent
and plasmids was changed with fresh medium. After 48 h from the
ﬁrst transfection, the supernatants containing virus were harvested
and the cells were re-fed with new freshmedium and incubated for an-
other 24 h. Then the second round of the supernatants was collected
and combined togetherwith that from the ﬁrst round, and concentrated
by ultracentrifugation using P28S rotor at 25,000 rpm for 2.5 h at 4 °C.d by up-regulation of α-SMA expression. c. PK2 promoted KC differentiation indicated by
p-regulates PPARβ expression of FB co-culturedwith KC. All the bars represent the average
(*, P b 0.05; **, P b 0.01).
255X. He et al. / EBioMedicine 13 (2016) 248–2612.19. Effect of PK2 Expression on Mouse Model of Psoriasis
K14-VEGF male mice (two-month old) were housed under a
12:12 h light: dark cycle with food and water available ad libitum.
Mice were divided into 5 groups: the blank control group (C), PK2
over-expression group (P), negative control of over-expression
group (NP), PK2 knockdown group (S), and negative control of PK2
knockdown group (NS). NaCl (0.9%) solution, the lentivirus of PK2-
PLVX-puro and empty PLVX-puro, the retrovirus of psh-PK2 and
psh-Scr was delivered into above ﬁve groups mice respectively by
tail vein injection. Effects of virus on PK2 expression in mice were ex-
amined by skin IHC and blood ELISA. A series of psoriasis indexes
(levels of cytokines, redness, thickness, weight, and swelling of ear,
andweight of lymph nodes) weremeasured in mice. The levels of cy-
tokines in serum sampled from eye blood on day 0, 10, 20, and 30
were determined by ELISA. IHC analysis was used to detect some im-
mune indexes including CD3, CD4, CD8, CD31, and E-selectin of the
mouse ear.2.20. Statistics
For statistical analysis, data obtained from three independent exper-
iments were presented as mean± SD. All statistical analyses were two-
tailed, with 95% conﬁdence intervals (CI) and conducted usingFig. 6. The knockdown or overexpression of PK2 was interfered by virus. a, b. IHC analysis of PK
solution; NS: negative control of sh-PK2, retrovirus of psh-Scr; S: sh-PK2, retrovirus of psh-PK2
lentivirus of PK2-PLVX-puro. All the bars and line graphs represent the average of three inde
indicated by asterisks (*, P b 0.05; **, P b 0.01) versus control at each time point. C: control,
retrovirus of psh-PK2; NP: negative control of PLVX-PK2, the lentivirus of empty PLVX-puro;
average of three independent experiments± SD forﬁvemice in each group. Signiﬁcant statisticGraphPad prism 5. Results were analyzed using an unpaired t-test. Dif-
ferences were considered signiﬁcant when P b 0.05.3. Results
3.1. PK2 Level Is Abnormally High in Human Psoriatic Skin and Blood
To explore the psoriasis-triggering factor(s), extracts of healthy
human and psoriatic skinswere compared. Among the additional eluted
peaks observed in psoriatic skin extract (Fig. S1), we identiﬁed those
representing psoriasin and an endogenous cathelicidin antimicrobial
peptide LL-37, two peptides already known to be associated with the
disease (Lande et al., 2007). PK2 was identiﬁed as another prominent
disease biomarker (indicated by an arrow in Fig. S1b). Indeed, IHC stain-
ing (Fig. 1a & b) revealed that there aremuchmore PK2-positive cells in
psoriatic skin than that in healthy skin. Enzyme-linked immune sorbent
assay (ELISA) showed that PK2 level was dramatically increased in both
the skin and blood of psoriasis patients (Fig. 1c & d). Particularly, the ex-
pression of PK2 in psoriatic skin (~650 pg/g) was ~12 times higher than
that in normal skin (~50 pg/g) (Fig. 1c). The expression of PK2 in skin is
normally very low (Negri and Lattanzi, 2011). No signiﬁcant changewas
found in patient serum of other autoimmune diseases including inﬂam-
matory bowel diseases (IBDs, including Crohn's disease and ulcerative
colitis), atherosclerosis, and diabetes (Fig. 1d). Profound and speciﬁc2 in K14/VEGFmice skins. c. PK2 levels in blood of K14/VEGFmice. C: control, NaCl (0.9%)
; NP: negative control of PLVX-PK2, the lentivirus of empty PLVX-puro; P: PLVX-PK2, the
pendent experiments ± SD for ﬁve mice in each group. Signiﬁcant statistics difference
NaCl (0.9%) solution; NS: negative control of sh-PK2, retrovirus of psh-Scr; S: sh-PK2,
P: PLVX-PK2, the lentivirus of PK2-PLVX-puro. All the bars and line graphs represent the
s difference indicated by asterisks (*, P b 0.05; **, P b 0.01) versus control at each time point.
256 X. He et al. / EBioMedicine 13 (2016) 248–261over-production of PK2 in psoriasis patients indicated that it might be
responsible for causing the histopathological symptoms.
3.2. Bacterial Products Promote PK2 Production
To explore the origin of PK2, bacterial productswere applied to stim-
ulate Raw 264.7 murinemacrophage cell, which is the main cell type to
induce inﬂammation and to secrete PK2. As illustrated in Fig. 1e, normal
Raw 264.7 secreted little (~12.4 pg/ml) PK2 while LPS (50 ng/ml) and
bacterial DNA (2 μg/ml) induced 357 and 953.2 pg/ml PK2 production.
IL-1, the central player of inﬂammatory reactions and psoriatic plaques,
also promoted PK2 production. At the concentration of 50 ng/ml, IL-1β
induced 238.1 pg/ml PK2 production in Raw 264.7 (Fig. 1e).
3.3. PK2 Promotes IL-1 Production and Proliferation of Co-cutured KC and
FB
Effect of PK2 on proliferation of KC and FB, which are juxtaposing
cells in skin both affected by psoriasis, was examined. No proliferation
effect was observed when KC or FB was treated with PK2 (Fig. S2a &
b), but KC and FB proliferation was induced by PK2 in a concentration-
dependent manner when the two types of cells were co-cultured (Fig.
2a & Fig. S2c). KC, but not FB, produces biologically active IL-1, which
is able to activate many secondary cytokines in the skin (Kofoed et al.,
2015). In addition, IL-1R1, which is expressed in FB, not in KC, mediates
all IL-1 biological response (Chong et al., 2009). It was found that IL-1
secretion in KC was promoted by PK2 (Fig. 2b). Considering that IL-1
has a pronounced inﬂuence on skin homeostasis (Schroder, 1995), weFig. 7. Effects of PK2 knockdown or over-expression on psoriasis symptoms in K14/VEGF trans
with H&E. d–g. Changes of ear swelling (d), weight (e), thickness (f), andweight of lymph node
S: sh-PK2, retrovirus of psh-PK2; NP: negative control of PLVX-PK2, the lentivirus of empty PLVX
the average of three independent experiments ± SD for ﬁve mice in each group. Signiﬁcant sta
point.hypothesized that the proliferation effect of PK2 on KC and FB may be
mediated by IL-1. This hypothesis was supported by blockade of IL-1 re-
ceptor using IL-1 receptor antagonist (IL-1ra), which resulted in strong
inhibition of PK2-induced KC and FB proliferation (Fig. S2c). PK2 also
stimulated macrophage, another important epidermal cell type, to se-
cret IL-1 (Fig. 2c & d). Many other mitogenic and proinﬂammatory fac-
tors including keratinocyte growth factor (KGF), granulocyte
macrophage colony-stimulating factor (GM-CSF), IL-6, -8, and -10
were induced by PK2 when KC was co-cultured with FB but not when
KC or FB was cultured alone (Fig. 2e & l). In particular, KGF is a known
potent mitogen for keratinocytes hyperproliferation and has been pro-
posed to account for epidermal hyperplasia associated with psoriasis
(Finch et al., 1997; Kovacs et al., 2006; Kovacs et al., 2005). At the con-
centration of 0.2 nM, PK2 induced an up-to-29-fold elevation of KGF ex-
pression in FB when co-cultured with KC (Fig. 2l).3.4. PK2 Possibly ActivatesMAPK and AIM2 Signaling Pathways to Promote
IL-1 Secretion
As illustrated in Fig. 3a & b, PK2 induced phosphorylation of ERK1/2,
JNK and p38 in a concentration-dependent manner in both KC and LPS-
activated Raw 264.7 murine macrophage cells. Since MAPK signaling is
important for regulation of cell growth, differentiation, and control of
cellular responses to pro-inﬂammatory cytokines (Chang and Karin,
2001), its activation by PK2 may contribute to IL-1 production and cell
proliferation in KC and macrophage. IL-1 production induced by PK2
was blunted by inhibitors of MAPK signaling (Fig. S3). Fig. 3c shows
that PK2 strongly up-regulated absent in melanoma 2 (AIM2)genic mice. a, b. Change of mouse ear redness. c. Photomicrographs of ear sections stained
s (g). C: control, NaCl (0.9%) solution; NS: negative control of sh-PK2, retrovirus of psh-Scr;
-puro; P: PLVX-PK2, the lentivirus of PK2-PLVX-puro. All the bars and line graphs represent
tistics difference indicated by asterisks (*, P b 0.05; **, P b 0.01) versus control at each time
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signiﬁcantly increased the expression of caspase-1, which is engaged
by AIM2 to produce active IL-1β by catalyzing proteolytic cleavage of
pro-interleukin-1β (pro-IL-1β) (Man and Kanneganti, 2015).
3.5. PK2 Promotes Angiogenesis, Wound Healing and KC and FB
Differentiation
Considering that 1) PK2 promotes the secretion of IL-1 (Fig. 2b–d), a
key mediator in the initiation and maintenance of psoriatic plaques
(Mee et al., 2006); and 2) Psoriasis shares many features with wound
healing and is considered as a model of exaggerated wound healing
with contorted blood vessels (Morhenn et al., 2013; Shi et al., 2014), ef-
fects of PK2 on angiogenesis and wound healing are investigated. In-
creased angiogenesis and contorted blood vessels were observed after
by PK2 treatment (Fig. S4). PK2 (0.05 nanomolar) increased angiogene-
sis by 1.5-fold while basic ﬁbroblast growth factor (b-FGF) at the same
dose only increased 0.8-fold. As illustrated in Fig. S5, PK2 acceleratedFig. 8. Effects of PK2 knockdown or over-expression on mouse immunity. Immune indexes an
30 days. C: control, NaCl (0.9%) solution; NS: negative control of sh-PK2, retrovirus of psh-S
empty PLVX-puro; P: PLVX-PK2, the lentivirus of PK2-PLVX-puro. All the bars and line grap
group. Signiﬁcant statistics difference indicated by asterisks (*, P b 0.05; **, P b 0.01) versus conthe wound closure. At day 3, 5, and 7, 42.8, 21.6, and 7.6% residual
wound was observed in PK2 treatment group (2 μg/day/wound),
while that in vehicle group was 77.8, 44.6, and 32.1%, respectively. The
corresponding residual wound ratio was 77, 20.8, and 9.8% in the
group of epidermal growth factor (EGF) treatment, respectively.
Wound healing is signiﬁcantly accelerated in PK2 treatment compared
to normal and EGF treatment. Histopathological study showed that
PK2 accelerated the initiation and the end of inﬂammatory phase of
wound (Fig. 4a & b). Fibroblast-to-myoﬁbroblast (FTM) transition
plays an important role in cutaneous wound healing (Kovacs et al.,
2005). The expression of α smooth muscle actin (α-SMA), a marker of
smooth muscle cell differentiation and FTM transition (Gabbiani,
2003), was elevated by PK2 in myoﬁbroblasts of the granulation tissue
below the wound surface (Fig. 5a & b). After treatment by 0.2 nM PK2,
low level of keratin 1 and 5 and high level of involucrin were observed
in HaCaT KC, indicting HaCaT KC differentiation induced with PK2 (Fig.
5c). KC differentiation induced by PK2was further supported by the re-
sult that the expression of peroxisome proliferator-activated receptor βd their positive area scores of CD3 (a & b), CD4 (c & d), CD8 (e & f) of mouse ear within
cr; S: sh-PK2, retrovirus of psh-PK2; NP: negative control of PLVX-PK2, the lentivirus of
hs represent the average of three independent experiments ± SD for ﬁve mice in each
trol at each time point.
258 X. He et al. / EBioMedicine 13 (2016) 248–261(PPAR-β) was elevated in FB by PK2 in a dose-dependent manner (Fig.
5d & e).
3.6. PK2 Over-expression Aggravated Psoriasis While PK2 Knock-down
Inhibited Disease Development
All the results so far demonstrate that high level of PK2 activates IL-1
signaling pathway to producemost of the characteristic features of pso-
riasis. To evaluate thismechanism in vivo, we used animalmodels to test
effects of PK2 on psoriasis. Keratin 14 (K14)-vascular endothelial
growth factor (VEGF) transgenic mouse model precisely matches
human psoriasis in all features (Detmar et al., 1998; Xia et al., 2003).
As illustrated in Fig. S6, substantial over-expression of PK2 was indeed
observed in K14-VEGF psoriasis-like skins as well as in acute
imiquimod-induced psoriasis-like skins, conﬁrming our observations
from human psoriatic skin (Fig. 1a–c). The level of PK2 in two-month
old K14-VEGF mice (n = 20 each) was up-regulated by lentivirus-
mediated over-expression of PK2 or down-regulated by retrovirus-
mediated PK2-targeting short hairpin RNA (sh-PK2) (Fig. 6a–c). All
mice showed psoriasiform features prior to PK2 expression interfer-
ence, as indicated by erythematous and scaly ear skin (Fig. 7a–d).
Psoriasiform symptoms were gradually aggravated by PK2 over-
expression, as evaluated by increased ear redness, ear swelling, ear
weight, ear thickness, and lymph node weight (Fig. 7a–g). Down-
regulation of PK2 expression by sh-PK2, on the other hand, markedly
inhibited aggravation of symptom (Fig. 7a–g).Fig. 9. Effects of PK2 knockdown or over-expression on cytokines in mouse model. Cytokines o
17(i) in blood. C: control, NaCl (0.9%) solution; NS: negative control of sh-PK2, retrovirus of p
of empty PLVX-puro; P: PLVX-PK2, the lentivirus of PK2-PLVX-puro. All the bars and line gra
group. Signiﬁcant statistics difference indicated by asterisks (*, P b 0.05; **, P b 0.01) versus conHistological evaluation further supported the role of PK2 in psoriasis
progression. Psoriasis-like phenotypes, including epidermal hyperplasia
with acanthosis, an absence of the granular layer of epidermis, focal
parakeratosis, and the intralesional presence of mononuclear cells,
were observed in control K14-VEGF mice (Fig. 7c). These phenotypes
were more severe in PK2 over-expression mice but milder in sh-PK2
mice. Staining of CD3, CD4, CD8, CD31 and E-selectin positive cells re-
vealed more inﬂammatory cells in PK2 over-expression animals and
less inﬂammatory cells in mice treated with sh-PK2, compared to the
control animals (Fig. 8a–f & Fig. S7). Inﬂammation was much milder in
sh-PK2mice than that in other groups. Cytokines levels were chronical-
ly elevated in all mice (Fig. 9a–i). Most of these cytokines were quickly
elevated in the blood by PK2 over-expression while sh-PK2 markedly
inhibited their elevation. Noticeably, the most prominent elevation
was observed in IL-1 (IL-1α and IL-1β) and IL-17, keymediators in pso-
riasis pathogenesis (Fig. 9g–i). After 30 days of PK2 over-expression, the
levels of IL-1α and IL-1βwere increased by 20 to hundreds folds while
sh-PK2 signiﬁcantly blunted these changes (Fig. 9g & h) (Fig. 10).
4. Discussion
Psoriasis is a chronic systemic inﬂammatory and an autoimmune
skin disease. It is histologically characterized by KC hyperproliferation,
inﬂammation, and increased angiogenesis (Bachelez, 2005; Nestle
et al., 2009). Although considerable progress in understanding the com-
plex genetic, environmental, and immunological basis of psoriasis hasf INF-γ (a), IL-2 (b), IL-12 (c), IL-22 (d), IL-23 (e), TNF-α (f), IL-1α (g), IL-1β (h), and IL-
sh-Scr; S: sh-PK2, retrovirus of psh-PK2; NP: negative control of PLVX-PK2, the lentivirus
phs represent the average of three independent experiments ± SD for ﬁve mice in each
trol at each time point.
Fig. 10. Schematic illustration of cell signaling network underlying PK2's key role in the process of psoriasis and PK2-IL-1 positive feedback loop. PK2 stimulates KC and macrophages to
produce IL-1. The released IL-1 acts on adjacent FB to promote secretion of multiple mitogenic and proinﬂammatory cytokines that consequently exerted proliferative and differentiating
effects on KC and FB. The predominant IL-1 receptor in KC is IL-1R2, which is incapable of participating in IL-1 signaling, while that in FB is IL-1R1, which mediates all IL-1 biological
response. The cytokines and chemokines produced by FB, in turn, recruit and activate immunocytes, leading to vicious cycle of inﬂammation. In addition, PK2 promotes angiogenesis.
259X. He et al. / EBioMedicine 13 (2016) 248–261been achieved, psoriasis pathogenesis remains not fully elucidated.
Many biomarker candidates of psoriasis have been found, but none of
them has so far met the sensitivity, speciﬁcity, and accuracy criteria
that would allow their translation into clinical use (Villanova et al.,
2013). Especially, limited information is available on psoriasis
histopathogenesis related with chronic erythematous plaques, which
is considered to be caused by KC hyperproliferation and abnormal an-
giogenesis. Although over-expression of vascular permeability factor/
vascular endothelial growth factor and its receptors is found in psoriasis
tissue, the factor responsible for contorted blood vessels in psoriatic le-
sions remains unknown (Detmar et al., 1994).
PK2 has been recently proposed to participate in numerous impor-
tant physiological processes including inﬂammation, neurogenesis, tis-
sue development, angiogenesis, and even nociception (Monnier and
Samson, 2010; Negri et al., 2004; Shojaei et al., 2008). It exerts the ac-
tions by binding to two G protein-coupled receptors, PKR1 and PKR2
(Cheng et al., 2012; Lattanzi et al., 2001; Negri et al., 2004). PKR1 is ex-
clusively responsible for mediating the modulation of macrophage
cytokine production. PK2 is mainly expressed in brain but can also
be found in skin, bone marrow, lymphoid organs, granulocytes, den-
dritic cells, macrophages, etc. (Martucci et al., 2006; Negri et al.,
2007). PKRs are distributed in brain and the peripheral organs, in-
cluding the spleen, and leukocytes, and they are found in most mu-
rine immune cell types (Dorsch et al., 2005; Franchi et al., 2008;
Martucci et al., 2006). PK2 and its receptors are less expressed in
skin but in this study, abnormally high PK2 level was found in
human psoriatic skin and blood as well as mouse psoriatic skin and
blood, but no signiﬁcant change in other autoimmune diseases, sug-
gesting that PK2 is a psoriasis-speciﬁc factor. PK2 is a multifunctional
cytokine possessing abilities to induce epidermal, vascular and in-
ﬂammatory change (Martucci et al., 2006; Monnier and Samson,
2010) as found in natural psoriasis.Why and how are PK2 overexpressed in psoriasis? One of the best-
characterized psoriasis initiation mechanisms is the antimicrobial pep-
tide LL-37-DNA/RNA complex resulted from infection or physical trau-
ma (Di Meglio et al., 2014), which induces inﬂammation, but how to
initiate and develop psoriasis remains unknown. As illustrated in Fig.
1e, bacterial products including LPS and DNA promoted the production
of PK2 besides inﬂammatory factors, suggesting that infection is a pri-
mary inducer of PK2 and inﬂammation.
Our results suggested that PK2 aggravates psoriasis by promotingKC
and FB proliferation and differentiation, inﬂammation, and angiogene-
sis. Besides the well-known angiogenesis function of PK2, how did
PK2 play the roles in psoriasis? PK2 signiﬁcantly induced production
of IL-1 in KC and macrophage. It is well known that TNF-a, IL-23, IL-17
and some other cytokines play important roles in psoriasis. These cyto-
kines were up-regulated by PK2 in vivo but not obvious in KC or macro-
phage in our study. IL-1 plays multiple roles in the initiation of an
inﬂammatory response to injury. In psoriasis, dysregulation of IL-1α
and IL-1β plays signiﬁcant roles in orchestrating the immune response
(Cooper et al., 1990; Johnston et al., 2011; Perera et al., 2012). IL-1 is a
direct chemoattractant to lymphocytes and exerts a further paracrine
effect (Chung et al., 2009; Nourshargh et al., 1995). This may be why
TNF-a, IL-23, IL-17 and some other cytokines were up-regulated by
PK2 in vivo but not in vitro. IL-1 is the most likely initiator of the KC ac-
tivation cycle (Perera et al., 2012). IL-1 is the inducer of nearly all other
proinﬂammatory cytokines and is able to activate secondary cytokines
in the skin (Schroder, 1995). The secreted IL-1 induced by PK2, which
acts on adjacent ﬁbroblast (FB), promoted the secretion of mitogenic
and proinﬂammatory factors and consequently exerted proliferative
and differentiation effects on KC and FB. Why was the co-culture of KC
and FB required for the proliferation effect of PK2 as the result showed?
The predominant IL-1 receptor in KC is IL-1R2,which is incapable of par-
ticipating in IL-1 signaling, while that in FB is IL-1R1, whichmediates all
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by KC and macrophage likely acted in a paracrine fashion on adjacent
FB, triggering the release of other cytokines to regulate proliferation of
both KC and FB (Chong et al., 2009; Kovacs et al., 2005). This possibility
was supported by observations that manymitogenic and proinﬂamma-
tory factors including KGF, GM-CSF, IL-6, -8, and -10 were induced by
PK2 when KC was co-cultured with FB but not when KC or FB was cul-
tured alone.
In addition to promoting KC and FB proliferation and inﬂammation,
PK2 induced HaCat keratinocyte differentiation. The use of normal
human keratinocytes (NHKs) is a primary choice to study molecular
mechanisms on the regulation of epidermal differentiation markers, as
an easy to handle substitutes for primary human keratinocytes, the im-
mortalized human keratinocyte cell line HaCaT has been widely used in
mechanistic and pharmacological studies of potential skin drugs (Seo
et al., 2012). Although HaCaT cells displayed some different attributes
compared to NHKs, such as it displayed enhanced sensitivity to lethal
doses of UV irradiation as compared to NHKs due to mutations leading
to the lack of intact p53 alleles and a complete loss of p53 DNA-
binding capacity (Pastore et al., 2011). As an alternative system,
HaCaT cells maintained normal keratinocyte morphology and epider-
mal differentiation capacity, remained non-tumorigenic, and
underwent, like normal human keratinocytes (Pastore et al., 2011). In
this study, HaCat cells were used to study the differentiation function
of PK2 on keratinocytes. KC differentiation induced by PK2 was further
supported by the result that the expression of PPAR-β, which was
found to exert potent pro-differentiating action in KC and possibly in-
volved in psoriasis pathology (Romanowska et al., 2008; Schmuth
et al., 2004; Westergaard et al., 2001), was elevated in FB by PK2. In
wound healing mouse model, PK2 exerted promoting ﬁbroblast dif-
ferentiation to myoﬁbroblast and accelerating inﬂammation. Both
in vitro (HUVEC) and in vivo (CAM) angiogenesis assays show that
PK2 leaded a markedly distorted, dilated, and contorted vascular
phenotype, which is a distinguishing feature of psoriasis (Di Meglio
et al., 2014; Perera et al., 2012). The results indicated that PK2 pro-
moted KC and FB proliferation and differentiation, inﬂammation,
and angiogenesis, which are all pathologic features of psoriasis
(Shi et al., 2014).
All the results indicated PK2 stimulates IL-1 production, which plays
important roles in the pathogenetic process of psoriasis. In addition to
activation of MAPK signaling pathways, PK2 is found to up-regulate
AIM2 inﬂammasome signal. The inﬂammasome is responsible for the
synthesis and secretion of proinﬂammatory cytokine IL-1β (Schroder,
1995). The formation of inﬂammasome and the synthesis of IL-1β are
of paramount importance for the pathogenesis of psoriasis (Schroder,
1995). In turn, IL-1 secretion induced by PK2 promoted PK2 production.
The interaction between PK2 and IL-1 makes a PK2-IL-1 vicious circle to
possibly sustain inﬂammation, KC hyperproliferation, and abnormal an-
giogenesis in psoriasis.
Over-expression of PK2 was observed in both K14-VEGF psoriasis-
like skins and acute imiquimod-induced psoriasis-like skins, which is
consistent with the results found in the human psoriatic skin. Over-
production of PK2 caused most of the psoriatic symptoms including in-
ﬂammation, angiogenesis, and KC hyperplasia while down-regulation
of PK2 inhibited psoriatic development. Our results suggest that patho-
logical increases in the level of PK2, in both human and K14-VEGF pso-
riatic skins, likely induce perpetuated disease cycle through stimulation
of IL-1 production, the release of multiple cytokines and chemokines,
and growth of keratinocytes and angiogenesis, as observed in psoriasis.
Althoughmany details of molecular events remain to be elucidated, it is
clear that PK2 plays a prominent role in this cell signaling network.
These ﬁndings also provide a molecular explanation for the observation
that expression of PK2 increases following inﬂammation (Negri and
Lattanzi, 2011). Therefore, it presents a prominent biomarker for diag-
nosis as well as a promising novel target for psoriasis therapeutic
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